Acumen Pharmaceuticals, Inc. ABOS
0.23 USD +0.01 (+6.53%)
Regular-session close
0.21 -0.02 -8.74%
After hours · Nov 17, 7:21 PM ET
0.203 Day range 0.2328
0.21 52-week range 3.37
- YTD
- -89.09%
- 1 year
- -85.44%
News
fool.com Acumen Pharmaceuticals: 3 Key Takeaways for Long-Term Investors Phase II ALTITUDE-AD trial top-line results are expected in November 2026. Cash reserves of $79 million will support operations into early 2027.
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) stock moved upwards by 16.2% to $4.67 during Monday's after-market session. The market value of their outstanding shares is at $9.1 million. Cerus…
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Inovio Pharmaceuticals (NASDAQ:INO) shares rose 211.2% to $1.88 during Monday's regular session. The company's market cap stands at $62.2 million. BeyondSpring (NASDAQ:BYSI) stock moved…
benzinga.com Regeneron Pharmaceuticals To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Monday Analysts upgraded MHK and CRWD, downgraded PFSI, cut ABOS’s target, and raised targets for NRXP, REGN and NTSK.benzinga.com BTIG Maintains Buy on Acumen Pharmaceuticals, Lowers Price Target to $1 BTIG analyst Thomas Shrader maintains Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and lowers the price target from $8 to $1.
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Inovio Pharmaceuticals (NASDAQ:INO) stock moved upwards by 292.6% to $2.37 during Friday's after-market session. The market value of their outstanding shares is at $79.8 million. Capricor…benzinga.com Citigroup Downgrades Acumen Pharmaceuticals to Neutral, Lowers Price Target to $1 Citigroup analyst Geoff Meacham downgrades Acumen Pharmaceuticals (NASDAQ:ABOS) from Buy to Neutral and lowers the price target from $5 to $1.
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers CareDx (NASDAQ:CDNA) shares rose 22.2% to $87.42 during Friday's regular session. The company's market cap stands at $3.7 billion. As per the press release, Q3 earnings came out yesterday.…
benzinga.com Nasdaq Down Over 600 Points; Amazon Shares Fall Following Weak Q3 Results U.S. stocks fell Friday, with Nasdaq down 2.36% as Amazon missed Q3 estimates. Acumen plunged 85%, while oil rose 1.8% and gold fell 1.7%.
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers NRX Pharmaceuticals (NASDAQ:NRXP) shares increased by 12.0% to $2.98 during Friday's pre-market session. The market value of their outstanding shares is at $115.1 million. Intensity…benzinga.com Acumen Pharma Says ALTITUDE-AD Missed Primary, Key Secondary Endpoints In Alzheimer's Study; Co. To Cease Clinical Development Of Sabirnetug, Preserve Cash And Explore Strategic Options -- Topline data show that ALTITUDE-AD did not meet the primary endpoint of change from baseline in cognitive and functional decline as measured by the Integrated Alzheimer’s Disease Rating Scale…
globenewswire.com Acumen Pharmaceuticals Announces Topline Results from Phase 2 ALTITUDE-AD Clinical Trial of Sabirnetug (ACU193) for the Treatment of Early Alzheimer's Disease; Trial Did Not Meet Primary Endpoint -- Topline data show that ALTITUDE-AD did not meet the primary endpoint of change from baseline in cognitive and functional decline as measured by the Integrated Alzheimer's Disease Rating Scale…
seekingalpha.com Acumen Pharmaceuticals: A Speculative Buy Ahead Of November's Alzheimer's Readout Acumen Pharmaceuticals is rated a speculative Buy ahead of November 2026 Phase 2 ALTITUDE-AD data for sabirnetug in early Alzheimer's disease. I estimate ABOS fair value at $2.57 per share, a 14%…
seekingalpha.com Acumen Pharmaceuticals, Inc. (ABOS) Q3 2026 Earnings Call Transcript Acumen Pharmaceuticals, Inc. (ABOS) Q3 2026 Earnings Call Transcript
marketbeat.com Acumen Pharmaceuticals Q3 Earnings Call Highlights Acumen Pharmaceuticals NASDAQ: ABOS said it expects to report top-line results in November from its Phase II ALTITUDE-AD trial of sabirnetug, an investigational antibody designed to target soluble…
benzinga.com Acumen Pharmaceuticals Q3 2026 Earnings Call Transcript Acumen Pharmaceuticals (NASDAQ:ABOS) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…benzinga.com Acumen Pharmaceuticals Q3 EPS $(0.35) Beats $(0.37) Estimate Acumen Pharmaceuticals (NASDAQ:ABOS) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.37) by 5.41 percent. This is a 20.45 percent increase over losses…
globenewswire.com Acumen Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Highlights Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease, in November 2026 IND filing for the Enhanced Brain…benzinga.com Acumen Pharmaceuticals To Present New Phase 2 ALTITUDE-AD Data For Sabirnetug In Early Alzheimer’s Disease At CTAD 2026 Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) (Acumen), a clinical-stage biopharmaceutical company developing novel therapeutics that target soluble amyloid beta oligomers (AβOs) for the treatment of…
globenewswire.com Acumen Pharmaceuticals to Present Preliminary Baseline Characteristics and Data on Care Experiences and Participation in Phase 2 ALTITUDE-AD Trial at the 19th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference NEWTON, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (Acumen), a clinical-stage biopharmaceutical company developing novel therapeutics that target soluble…
globenewswire.com Acumen Pharmaceuticals to Report Third Quarter Financial Results on October 26, 2026 NEWTON, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that…
zacks.com 4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day Four biotech stocks advance Alzheimer's therapies, from marketed treatments to experimental programs targeting amyloid and tau.
seekingalpha.com Acumen Pharmaceuticals, Inc. (ABOS) Analyst/Investor Day Transcript Acumen Pharmaceuticals, Inc. (ABOS) Analyst/Investor Day Transcript
globenewswire.com Acumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026 NEWTON, Mass., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics…
seekingalpha.com Acumen Pharmaceuticals, Inc. (ABOS) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript Acumen Pharmaceuticals, Inc. (ABOS) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
globenewswire.com Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences NEWTON, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble…
defenseworld.net ADAR1 Capital Management LLC Makes New Investment in Acumen Pharmaceuticals, Inc. $ABOS ADAR1 Capital Management LLC acquired a new position in shares of Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) during the second quarter, according to the company in its most recent filing with the…
seekingalpha.com Acumen Pharmaceuticals, Inc. (ABOS) Q2 2026 Earnings Call Transcript Acumen Pharmaceuticals, Inc. (ABOS) Q2 2026 Earnings Call Transcript
marketbeat.com Acumen Pharmaceuticals Q2 Earnings Call Highlights Acumen Pharmaceuticals NASDAQ: ABOS said it remains on track to report top-line results late in 2026 from its Phase II ALTITUDE-AD study of sabirnetug, an investigational antibody designed to…
globenewswire.com Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights NEWTON, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that…
globenewswire.com Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 12, 2026 NEWTON, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that…
zacks.com Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year? Here is how Acumen Pharmaceuticals, Inc. (ABOS) and Amarin (AMRN) have performed compared to their sector so far this year.
zacks.com All You Need to Know About Acumen Pharmaceuticals (ABOS) Rating Upgrade to Buy Acumen Pharmaceuticals (ABOS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
